Schizophrenia in later life

American Journal of Geriatric Psychiatry

Volumn 20, Issue 1, 2012, Pages 1-4

  Harvey, Philip D ^a,b   Czaja, Sara J ^a   Loewenstein, David A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; OLANZAPINE;

AGE; AGING; AUTISM; COGNITION; COMORBIDITY; CROSS-SECTIONAL STUDY; HUMAN; LONGITUDINAL STUDY; METABOLIC SYNDROME X; NEUROPSYCHOLOGICAL TEST; ONSET AGE; PREVALENCE; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SUICIDAL BEHAVIOR;

EID: 84155165487     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1097/JGP.0b013e31823bbf93     Document Type: Editorial

References (12)

1. Meesters PD, de Haan L, Comijs HC, et al: Schizophrenia spectrum disorders in later life: prevalence and distribution of age at onset and sex in a Dutch catchment area. Am J Geriatr Psychiatry 2012; 20:18-28
2. Cohen CI, Cohen GD, Blank K, et al: Schizophrenia and older adults. An overview: directions for research and policy. Am J Geriatr Psychiatry 2000; 8(1):19-28
3. Loewenstein DA, Czaja S, Bowie CR, et al: Age-associated differences in cognitive performance in older patients with schizophrenia: a comparison with healthy older adults. Am J Geriatr Psychiatry 2012; 20:29-40
4. Irani F, Brensinger CM, Richard J, et al: Computerized neurocogni-tive test performance in schizophrenia: a lifespan analysis. 2012; 20:41-52
5. Keefe RS, Bilder RM, Harvey PD, et al: Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharma-cology 2006; 31:2033-2046
6. Silverstein SM, All SD, Jaeger J: Cognition-UPSA score relationships: a further analysis of Silverstein et al. (2010) data and some caveats. Psychiatry Res 2011; 187:424-431
7. Silver JM, Koumaras B, Chen M, et al: The effects of rivatsig-mine on cognitive function in patients with traumatic brain injury. Neurology 2006; 67:748-755
8. Harvey PD, Hsu J, Cucchiaro J, et al: Cognitive performance in patients with acute schizophrenia treated with Lurasidone. A double-blind randomized trial. Paper presented at: Annual Meeting of the American Psychiatric Association; August 4-7. Washington DC; 2011
9. Harvey PD, Reichenberg A, Bowie CR, et al: The course of neu-ropsychological performance and functional capacity in older patients with schizophrenia: influences of previous history of long-term institutional stay. Biol Psychiatry 2010; 67:933-939
10. Friedman JI, Harvey PD, Coleman T, et al: A six-year follow-up across the life-span in schizophrenia: a comparison with Alzheimer's Disease and Healthy Subjects. Am J Psychiatry 2001; 158:1441-1448
11. Ismail Z, Wessels AM, Uchida H, et al: Age and sex impact clozapine plasma concentrations in inpatients and outpatients with schizophrenia. Am J Geriatr Psychiatry 2012; 20: 53-60
12. Morrato EH, Newcomer JW, Kamat S, et al Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes Care 2009; 32: 1037-1042